Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation
Authors:
- 1 July 2022
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 109 (3) , 298-304
Abstract
Background: Herpes zoster (HZ) is a frequent complication after autologous stem cell transplantation (ASCT). The option of zoster prophylaxis with an antiviral drug is described in the literature, but there is no consensus on the drug and the dosage.Patients and Methods: We analyzed the records of 310 patients treated with ASCT who were controlled regularly regarding HZ inter alia for at least 24 months following ASCT. Since 01/2015 patients received prophylactic low‐dose acyclovir (400 mg per day) during the first 12 months following discharge after ASCT (n = 107).Results: Twenty percent of patients without this kind of prophylaxis and 2.8% of patients with prophylaxis developed HZ (p < .001). No patient with this prophylaxis developed HZ in the first year after ASCT, 2.8% of patients in the second year after ASCT. A prognostic factor was the kind of diagnosis: 30% of lymphoma patients and 14% of myeloma patients developed HZ in the first 24 months after ASCT without prophylaxis, but only 6.3% and 0% of patients with prophylaxis, respectively. Neither an increase of HZ cases following prophylaxis nor acyclovir refractory HZ cases were observed.Conclusions: Zoster prophylaxis with low‐dose acyclovir over 12 months after ASCT is effective and well tolerated.Keywords
This publication has 28 references indexed in Scilit:
- A Japanese single‐hospital observational trial with a retrospective case‐control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantationTransplant Infectious Disease, 2015
- Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantationInternational Journal of Hematology, 2015
- Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipientsAnnals of Hematology, 2013
- Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant populationTransplant Infectious Disease, 2011
- Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective StudyJapanese Journal of Clinical Oncology, 2010
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- Incidence and Risk of Postherpetic Neuralgia after Varicella Zoster Virus Infection in Hematopoietic Cell Transplantation Recipients: Hokkaido Hematology Study GroupTransplantation and Cellular Therapy, 2009
- One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuationBlood, 2007
- Späte infektiöse Komplikationen nach Hochdosistherapie und autologer BlutstammzelltransplantationMedizinische Klinik, 2002
- Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescueBone Marrow Transplantation, 1999